Cargando…

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the sixth cause of death from cancer in the USA. Autologous stem cell transplantation (ASCT) is a potentially curative therapeutic option for many NHL patients. Choosing the most effective conditioning regimen prior to ASCT can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eskian, Mahsa, Khorasanizadeh, MirHojjat, Isidori, Alessandro, Rezaei, Nima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176953/ https://www.ncbi.nlm.nih.gov/pubmed/30302233 http://dx.doi.org/10.2217/ijh-2017-0025

Ejemplares similares

Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma
por: Mahdaviani, Seyed Alireza, et al.
Publicado: (2021)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Cardiovascular risk assessment by FRS and SCORE in Iranian adult population
por: Meysamie, Alipasha, et al.
Publicado: (2017)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma
por: Ron-Magaña, Ana Lucia, et al.
Publicado: (2019)

Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
por: Tian, Chen, et al.
Publicado: (2021)

The effect of insomnia on development of Alzheimer’s disease
por: Sadeghmousavi, Shaghayegh, et al.
Publicado: (2020)

Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
por: Cortez, Afonso José Pereira, et al.
Publicado: (2011)

Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritti, Giuseppe, et al.
Publicado: (2018)

Single-Agent High-Dose Melphalan as Conditioning Regimen in Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma: Safety, and Long-Term Efficacy
por: Al Hashmi, Hani, et al.
Publicado: (2018)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
por: Burdick, Michael J, et al.
Publicado: (2009)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
por: Domingo-Domènech, Eva, et al.
Publicado: (2020)

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritt, Giuseppe, et al.
Publicado: (2018)

Autologous Stem Cell Transplantation for Aggressive Lymphomas
por: Visani, Giuseppe, et al.
Publicado: (2012)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma – characteristics and risk factor analysis
por: Czyż, Anna, et al.
Publicado: (2013)

P1367: COMPARISON CONDITIONING REGIMENS (BEEAC,LEAM,CLV) BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS HODGKIN’S LYMPHOMA
por: Samoylova, A., et al.
Publicado: (2022)

Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS
por: Sharma, Atul, et al.
Publicado: (2013)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation
por: Currin, Erin-Siobhain R., et al.
Publicado: (2012)

Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
por: Castagna, Luca, et al.
Publicado: (2015)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
por: Samara, Yazeed, et al.
Publicado: (2022)

Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma
por: Fukui, Yuta, et al.
Publicado: (2022)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
por: Shabbir-Moosajee, Munira, et al.
Publicado: (2019)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy
por: Kesavan, Murali, et al.
Publicado: (2017)

The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation
por: Jeon, So Yeon, et al.
Publicado: (2018)

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective
por: Reid, Robin M., et al.
Publicado: (2016)

The role of transplantation in Hodgkin lymphoma
por: Maranzano, Michael, et al.
Publicado: (2023)

Successful Repigmentation of Vitiligo after Allogeneic Bone Marrow Transplantation for Hodgkin's Lymphoma by Autologous Noncultured Melanocyte-keratinocyte Transplantation
por: Tang, Huijuan, et al.
Publicado: (2015)

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience
por: Chang, Hyun, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_kgghppiiesdv0tgrcq8kuhjbmu